{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:32:01Z","timestamp":1784658721965,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kakar","award":["UO1 CA18514"],"award-info":[{"award-number":["UO1 CA18514"]}]},{"name":"Kakar","award":["T32 HL134644"],"award-info":[{"award-number":["T32 HL134644"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ovarian cancer is the fifth leading cause of cancer-related deaths amongst women in the United States. Cachexia is the primary cause of death in approximately 30% of cancer patients, and is often evidenced in ovarian cancer patients. We tested the steroidal lactone Withaferin A to examine if it could ameliorate ovarian cancer-induced cachexia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Six-week-old severely immunodeficient female mice were xenografted with the ovarian cancer cell line A2780 followed by treatment with Withaferin A or vehicle. Changes in functional grip strength were assessed on a weekly basis. Postmortem, H&amp;E staining was performed on skeletal muscle sections and immunofluorescent immunohistochemistry was performed on skeletal muscle and tumor sections. The levels of NF-\u03baB-related proinflammatory cytokines were assessed in the xenografted tumors and in resident host skeletal muscle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Xenografting of the A2780 cell line resulted in a significant rate of mortality, which was attenuated by a therapeutic dosage of Withaferin A. Mice that received vehicle treatment following xenografting exhibited functional muscle decline over the course of the study. The therapeutic dosage Withaferin A treatment attenuated this reduction in grip strength, whereas the supratherapeutic dosage of Withaferin A was found to be toxic\/lethal and demonstrated a further decline in functional muscle strength and an increased rate of mortality on par with vehicle treatment. At a histological level, the vehicle treated tumor-bearing mice exhibited a profound reduction in myofibrillar cross-sectional area compared to the vehicle treated tumor-free control group. The atrophic changes induced by the xenografted tumor were significantly ameliorated by treatment with Withaferin A. The combination of functional muscle weakening and induction of myofibrillar atrophy corroborate a cachectic phenotype, which was functionally rescued by Withaferin A. Further, treatment completely abolished the slow-to-fast myofiber type conversion observed in the settings of cancer-induced cachexia. In both host resident skeletal muscle and the xenografted tumors, we report an increase in NF-\u03baB-related proinflammatory cytokines that was reversed by Withaferin A treatment. Finally, we demonstrated that Withaferin A significantly downregulates cytosolic and nuclear levels of phospho-p65, the active canonical NF-\u03baB transcription factor, in xenografted tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cumulatively, our results demonstrate a previously overlooked role of Withaferin A in a xenograft model of ovarian cancer. We propose mechanisms by which Withaferin A reduces NF-\u03baB-dependent pro-inflammatory cytokine production leading to an attenuation of the cachectic phenotype in an i.p. xenograft model of ovarian cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-019-0586-1","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T13:02:38Z","timestamp":1574686958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6516-8096","authenticated-orcid":false,"given":"Alex R.","family":"Straughn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-2625","authenticated-orcid":false,"given":"Sham S.","family":"Kakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"1","key":"586_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. Ca-a Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"Ca-a Cancer J Clin"},{"issue":"3","key":"586_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053\u201364.","journal-title":"Am J Pathol"},{"issue":"24","key":"586_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"17","key":"586_CR4","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194\u2013200.","journal-title":"J Clin Oncol"},{"issue":"11","key":"586_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","volume":"19","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010;19(11):1339\u201354.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"586_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminoncol.2008.12.003","volume":"36","author":"LP Martin","year":"2009","unstructured":"Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol. 2009;36(2):112\u201325.","journal-title":"Semin Oncol"},{"issue":"3","key":"586_CR7","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Phys Endocrinol Metab. 2012;303(3):E410\u201321.","journal-title":"Am J Phys Endocrinol Metab"},{"issue":"7","key":"586_CR8","doi-asserted-by":"publisher","first-page":"e22538","DOI":"10.1371\/journal.pone.0022538","volume":"6","author":"A Bonetto","year":"2011","unstructured":"Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011;6(7):e22538.","journal-title":"PLoS One"},{"issue":"5","key":"586_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"2","key":"586_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153\u201366.","journal-title":"Cell Metab"},{"issue":"4","key":"586_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jcsm.12311","volume":"9","author":"F Pin","year":"2018","unstructured":"Pin F, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, Zimmers TA, Couch ME, Bonewald LF, Bonetto A. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685\u2013700.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"586_CR12","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e80","volume":"28","author":"Z Hilal","year":"2017","unstructured":"Hilal Z, Rezniczek GA, Klenke R, Dogan A, Tempfer CB. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis. J Gynecol Oncol. 2017;28(6):e80.","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"586_CR13","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.biocel.2013.05.032","volume":"45","author":"N Johns","year":"2013","unstructured":"Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol. 2013;45(10):2215\u201329.","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"586_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/IGC.0000000000000867","volume":"27","author":"H Bronger","year":"2017","unstructured":"Bronger H, Hederich P, Hapfelmeier A, Metz S, Noel PB, Kiechle M, Schmalfeldt B. Sarcopenia in advanced serous ovarian cancer. Int J Gynecol Cancer. 2017;27(2):223\u201332.","journal-title":"Int J Gynecol Cancer"},{"issue":"28","key":"586_CR15","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","volume":"7","author":"R Barreto","year":"2016","unstructured":"Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, Bonetto A. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs. Oncotarget. 2016;7(28):43442\u201360.","journal-title":"Oncotarget"},{"issue":"7","key":"586_CR16","doi-asserted-by":"publisher","first-page":"e42265","DOI":"10.1371\/journal.pone.0042265","volume":"7","author":"MY Fong","year":"2012","unstructured":"Fong MY, Jin S, Rane M, Singh RK, Gupta R, Kakar SS. Withaferin a synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One. 2012;7(7):e42265.","journal-title":"PLoS One"},{"issue":"4","key":"586_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbrc.2012.06.047","volume":"423","author":"SS Kakar","year":"2012","unstructured":"Kakar SS, Jala VR, Fong MY. Synergistic cytotoxic action of cisplatin and withaferin a on ovarian cancer cell lines. Biochem Biophys Res Commun. 2012;423(4):819\u201325.","journal-title":"Biochem Biophys Res Commun"},{"issue":"43","key":"586_CR18","doi-asserted-by":"publisher","first-page":"74494","DOI":"10.18632\/oncotarget.20170","volume":"8","author":"SS Kakar","year":"2017","unstructured":"Kakar SS, Parte S, Carter K, Joshua IG, Worth C, Rameshwar P, Ratajczak MZ. Withaferin a (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017;8(43):74494\u2013505.","journal-title":"Oncotarget"},{"issue":"9","key":"586_CR19","doi-asserted-by":"publisher","first-page":"e107596","DOI":"10.1371\/journal.pone.0107596","volume":"9","author":"SS Kakar","year":"2014","unstructured":"Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, Miller DM, Batra SK, Singh SK. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells. PLoS One. 2014;9(9):e107596.","journal-title":"PLoS One"},{"issue":"2","key":"586_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14343\/JCSCR.2016.4e1002","volume":"4","author":"Sham S. Kakar","year":"2016","unstructured":"Kakar SS, Worth CA, Wang Z, Carter K, Ratajczak M, Gunjal P. DOXIL when combined with Withaferin a (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res. 2016;4.","journal-title":"Journal of Cancer Stem Cell Research"},{"issue":"3","key":"586_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ygyno.2011.11.044","volume":"124","author":"X Zhang","year":"2012","unstructured":"Zhang X, Samadi AK, Roby KF, Timmermann B, Cohen MS. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin a. Gynecol Oncol. 2012;124(3):606\u201312.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"586_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/carcin\/bgy109","volume":"39","author":"B Chandrasekaran","year":"2018","unstructured":"Chandrasekaran B, Pal D, Kolluru V, Tyagi A, Baby B, Dahiya NR, Youssef K, Alatassi H, Ankem MK, Sharma AK, et al. The chemopreventive effect of withaferin a on spontaneous and inflammation-associated colon carcinogenesis models. Carcinogenesis. 2018;39(12):1537\u201347.","journal-title":"Carcinogenesis"},{"key":"586_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fphys.2017.00634","volume":"8","author":"HW Chang","year":"2017","unstructured":"Chang HW, Li RN, Wang HR, Liu JR, Tang JY, Huang HW, Chan YH, Yen CY. Withaferin a induces oxidative stress-mediated apoptosis and DNA damage in oral cancer cells. Front Physiol. 2017;8:634.","journal-title":"Front Physiol"},{"issue":"1","key":"586_CR24","doi-asserted-by":"publisher","first-page":"15737","DOI":"10.1038\/s41598-018-34018-1","volume":"8","author":"AH Kyakulaga","year":"2018","unstructured":"Kyakulaga AH, Aqil F, Munagala R, Gupta RC. Withaferin a inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells. Sci Rep. 2018;8(1):15737.","journal-title":"Sci Rep"},{"issue":"1","key":"586_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.yexcr.2018.04.015","volume":"368","author":"KJ Royston","year":"2018","unstructured":"Royston KJ, Paul B, Nozell S, Rajbhandari R, Tollefsbol TO. Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Exp Cell Res. 2018;368(1):67\u201374.","journal-title":"Exp Cell Res"},{"issue":"4","key":"586_CR26","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.bbrc.2018.06.162","volume":"503","author":"S Xia","year":"2018","unstructured":"Xia S, Miao Y, Liu S. Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells. Biochem Biophys Res Commun. 2018;503(4):2363\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"51","key":"586_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4103\/0973-1296.211042","volume":"13","author":"HL Zhang","year":"2017","unstructured":"Zhang HL, Zhang H. Withaferin-a induces apoptosis in osteosarcoma U2OS cell line via generation of ROS and disruption of mitochondrial membrane potential. Pharmacogn Mag. 2017;13(51):523\u20137.","journal-title":"Pharmacogn Mag"},{"issue":"2","key":"586_CR28","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1096\/fj.201800683RR","volume":"33","author":"Yann S. Gallot","year":"2019","unstructured":"Gallot YS, Bohnert KR, Straughn AR, Xiong G, Hindi SM, Kumar A. PERK regulates skeletal muscle mass and contractile function in adult mice. Faseb J. 2018;33:fj201800683RR.","journal-title":"The FASEB Journal"},{"issue":"68","key":"586_CR29","doi-asserted-by":"publisher","first-page":"112565","DOI":"10.18632\/oncotarget.22575","volume":"8","author":"YS Gallot","year":"2017","unstructured":"Gallot YS, McMillan JD, Xiong G, Bohnert KR, Straughn AR, Hill BG, Kumar A. Distinct roles of TRAF6 and TAK1 in the regulation of adipocyte survival, thermogenesis program, and high-fat diet-induced obesity. Oncotarget. 2017;8(68):112565\u201383.","journal-title":"Oncotarget"},{"issue":"1","key":"586_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jmcb\/mjy053","volume":"11","author":"AR Straughn","year":"2019","unstructured":"Straughn AR, Hindi SM, Xiong G, Kumar A. Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis. J Mol Cell Biol. 2019;11(1):53\u201366.","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"586_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1172\/JCI81655","volume":"126","author":"SM Hindi","year":"2016","unstructured":"Hindi SM, Kumar A. TRAF6 regulates satellite stem cell self-renewal and function during regenerative myogenesis. J Clin Invest. 2016;126(1):151\u201368.","journal-title":"J Clin Invest"},{"issue":"23","key":"586_CR32","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1158\/0008-5472.CAN-15-0706","volume":"75","author":"Y Liu","year":"2015","unstructured":"Liu Y, Metzinger MN, Lewellen KA, Cripps SN, Carey KD, Harper EI, Shi Z, Tarwater L, Grisoli A, Lee E, et al. Obesity contributes to ovarian cancer metastatic success through increased Lipogenesis, enhanced vascularity, and decreased infiltration of M1 macrophages. Cancer Res. 2015;75(23):5046\u201357.","journal-title":"Cancer Res"},{"issue":"1","key":"586_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1152\/jappl.1996.81.1.123","volume":"81","author":"VJ Caiozzo","year":"1996","unstructured":"Caiozzo VJ, Haddad F, Baker MJ, Herrick RE, Prietto N, Baldwin KM. Microgravity-induced transformations of myosin isoforms and contractile properties of skeletal muscle. J Appl Physiol (Bethesda, Md : 1985). 1996;81(1):123\u201332.","journal-title":"J Appl Physiol (Bethesda, Md : 1985)"},{"issue":"3","key":"586_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MCO.0b013e328360272d","volume":"16","author":"Y Wang","year":"2013","unstructured":"Wang Y, Pessin JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2013;16(3):243\u201350.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"5","key":"586_CR35","doi-asserted-by":"publisher","first-page":"C1376","DOI":"10.1152\/ajpcell.00154.2002","volume":"283","author":"GM Diffee","year":"2002","unstructured":"Diffee GM, Kalfas K, Al-Majid S, McCarthy DO. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol. 2002;283(5):C1376\u201382.","journal-title":"Am J Physiol Cell Physiol"},{"key":"586_CR36","unstructured":"Chromiak JA, Antonio J. Skeletal muscle plasticity. In: Antonio J, Kalman D, Stout JR, Greenwood L, Willoughby DS, Half GG, editors. Essentials of Sports Nutrion and SUpplements. New York City: Humana Press; 2008. p. 21\u201352."},{"issue":"1","key":"586_CR37","first-page":"247","volume":"15","author":"X Cheng","year":"2018","unstructured":"Cheng X, Song L, Lan M, Shi B, Li J. Morphological and molecular comparisons between tibialis anterior muscle and levator veli palatini muscle: a preliminary study on their augmentation potential. Exp Ther Med. 2018;15(1):247\u201353.","journal-title":"Exp Ther Med"},{"issue":"1","key":"586_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40635-016-0115-0","volume":"5","author":"N Huang","year":"2017","unstructured":"Huang N, Kny M, Riediger F, Busch K, Schmidt S, Luft FC, Slevogt H, Fielitz J. Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy. Intensive Care Med Exp. 2017;5(1):3.","journal-title":"Intensive Care Med Exp"},{"issue":"34","key":"586_CR39","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/onc.2008.112","volume":"27","author":"R Chen","year":"2008","unstructured":"Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 2008;27(34):4712\u201323.","journal-title":"Oncogene"},{"issue":"4","key":"586_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.bcp.2014.08.004","volume":"91","author":"K Heyninck","year":"2014","unstructured":"Heyninck K, Lahtela-Kakkonen M, Van der Veken P, Haegeman G, Vanden Berghe W. Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKbeta. Biochem Pharmacol. 2014;91(4):501\u20139.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"586_CR41","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1074\/jbc.M606728200","volume":"282","author":"M Kaileh","year":"2007","unstructured":"Kaileh M, Vanden Berghe W, Heyerick A, Horion J, Piette J, Libert C, De Keukeleire D, Essawi T, Haegeman G. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 2007;282(7):4253\u201364.","journal-title":"J Biol Chem"},{"issue":"1","key":"586_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcsm.12402","volume":"10","author":"MS Anker","year":"2019","unstructured":"Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, Morley JE, Strasser F, Landmesser U, Coats AJS, et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle. 2019;10(1):22\u201334.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"586_CR43","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.18632\/oncotarget.23364","volume":"9","author":"CM Chang","year":"2018","unstructured":"Chang CM, Wang ML, Lu KH, Yang YP, Juang CM, Wang PH, Hsu RJ, Yu MH, Chang CC. Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. Oncotarget. 2018;9(3):3704\u201326.","journal-title":"Oncotarget"},{"issue":"2","key":"586_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","volume":"58","author":"A Maccio","year":"2012","unstructured":"Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58(2):133\u201347.","journal-title":"Cytokine"},{"key":"586_CR45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2015.03.015","volume":"80","author":"P Londhe","year":"2015","unstructured":"Londhe P, Guttridge DC. Inflammation induced loss of skeletal muscle. Bone. 2015;80:131\u201342.","journal-title":"Bone"},{"issue":"1575","key":"586_CR46","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1098\/rstb.2011.0027","volume":"366","author":"JL Shadrach","year":"2011","unstructured":"Shadrach JL, Wagers AJ. Stem cells for skeletal muscle repair. Philos Trans R Soc Lond Ser B Biol Sci. 2011;366(1575):2297\u2013306.","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"586_CR47","doi-asserted-by":"crossref","unstructured":"Hindi SM, Sato S, Xiong G, Bohnert KR, Gibb AA, Gallot YS, McMillan JD, Hill BG, Uchida S, Kumar A. TAK1 regulates skeletal muscle mass and mitochondrial function. JCI Insight. 2018;3(3).","DOI":"10.1172\/jci.insight.98441"},{"key":"586_CR48","doi-asserted-by":"publisher","first-page":"30340","DOI":"10.1038\/srep30340","volume":"6","author":"Z Aversa","year":"2016","unstructured":"Aversa Z, Pin F, Lucia S, Penna F, Verzaro R, Fazi M, Colasante G, Tirone A, Rossi Fanelli F, Ramaccini C, et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci Rep. 2016;6:30340.","journal-title":"Sci Rep"},{"key":"586_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.freeradbiomed.2015.12.031","volume":"98","author":"O Rom","year":"2016","unstructured":"Rom O, Reznick AZ. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med. 2016;98:218\u201330.","journal-title":"Free Radic Biol Med"},{"key":"586_CR50","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.","journal-title":"Nat Commun"},{"issue":"9","key":"586_CR51","doi-asserted-by":"publisher","first-page":"e103988","DOI":"10.1371\/journal.pone.0103988","volume":"9","author":"CM Beaufort","year":"2014","unstructured":"Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IWF HAA, Smid M, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014;9(9):e103988.","journal-title":"PLoS One"},{"issue":"3","key":"586_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237\u201349.","journal-title":"Virchows Arch"},{"issue":"1","key":"586_CR53","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1038\/s41598-019-41941-4","volume":"9","author":"A Hallas-Potts","year":"2019","unstructured":"Hallas-Potts A, Dawson JC, Herrington CS. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci Rep. 2019;9(1):5515.","journal-title":"Sci Rep"},{"issue":"22","key":"586_CR54","doi-asserted-by":"publisher","first-page":"32810","DOI":"10.18632\/oncotarget.9053","volume":"7","author":"J Haley","year":"2016","unstructured":"Haley J, Tomar S, Pulliam N, Xiong S, Perkins SM, Karpf AR, Mitra S, Nephew KP, Mitra AK. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget. 2016;7(22):32810\u201320.","journal-title":"Oncotarget"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0586-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:26:55Z","timestamp":1606177615000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0586-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"24 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving the usage of mice were carried out in strict accordance to the standards of the National Institute of Health guide for the care and use of laboratory animals. The Institutional Animal Care and Use Committee (IACUC, protocol # 15405) and Institutional Biosafety Committee (IBC, protocol # 18\u2013208) of the University of Louisville approved all experimental protocols in mice in advance.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors, Alex R. Straughn and Sham S. Kakar, declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}